NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Nelson HD, Huffman LH, Fu R, et al. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Sep. (Evidence Syntheses, No. 37.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility

Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility [Internet].

Show details

References

1.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26. [PubMed: 12568441]
2.
Gail MH, Brinton LA, Byar DP. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–1886. [PubMed: 2593165]
3.
Colditz GA, Willett WC, Hunter DJ. et al. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA. 1993;270(3):338–343. [PubMed: 8123079]
4.
American Cancer Society: Cancer Facts and Figures 2004. Atlanta, GA: American Cancer Society, 2004. Available at: http://www​.cancer.org​/downloads/STT/CAFF_finalPWSecured.pdf. Accessed April 30, 2004.
5.
Yang Q, Khoury MJ, Rodriguez C, Calle EE, Tatham LM, Flanders WD. Family history score as a predictor of breast cancer mortality: prospective data from the Cancer Prevention Study II, United States, 1982-1991. Am J Epidemiol. 1998;147(7):652–659. [PubMed: 9554604]
6.
Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA. 1993;270(13):1563–1568. [PubMed: 8371466]
7.
Johnson N, Lancaster T, Fuller A. The prevalence of a family history of cancer in general practice. Fam Pract. 1995;12(3):287–289. [PubMed: 8536831]
8.
Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71(5):800–809. [PubMed: 9180149]
9.
Miki Y, Swensen J, Shattuck-Eidens D. et al. A Strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71. [PubMed: 7545954]
10.
Wooster R, Bignell G, Lancaster J. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792. [PubMed: 8524414]
11.
Struewing JP, Hartge P, Wacholder S. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401–1408. [PubMed: 9145676]
12.
Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185–187. [PubMed: 8841191]
13.
Neuhausen S, Gilewski T, Norton L. et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics. 1996;13(1):126–128. [PubMed: 8673092]
14.
Peelen T, van Vliet M, Petrij-Bosch A. et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997;60(5):1041–1049. [PMC free article: PMC1712432] [PubMed: 9150151]
15.
Thorlacius S, Olafsdottir G, Tryggvadottir L. et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996;13(1):117–119. [PubMed: 8673089]
16.
Arason A, Jonasdottir A, Barkardottir RB. et al. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet. 1998;35(6):446–449. [PMC free article: PMC1051336] [PubMed: 9643283]
17.
Einbeigi Z, Bergman A, Kindblom LG. et al. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer. 2001;37(15):1904–1909. [PubMed: 11576847]
18.
Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348(23):2339–2347. [PubMed: 12788999]
19.
Lindor NM, Greene MH. Mayo Familial Cancer Program. The concise handbook of family cancer syndromes. J Natl Cancer Inst. 1998;90(14):1039–1071. [PubMed: 9672254]
20.
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22(4):735–742. [PubMed: 14966099]
21.
Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365–1372. [PubMed: 12237282]
22.
Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358–1365. [PubMed: 12237281]
23.
Easton D, Ford D, Bishop DT. The breast cancer linkage consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56(265–271). [PMC free article: PMC1801337] [PubMed: 7825587]
24.
Ford D, Easton D. The genetics of breast and ovarian cancer. Br J Cancer. 1995;72(805–812). [PMC free article: PMC2034018] [PubMed: 7547224]
25.
Ford D, Easton D, Bishop DT, Narod SA, Goldgar DE. The breast cancer linkage consortium. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343:692–695. [PubMed: 7907678]
26.
Easton D, Bishop DT, Ford D, Crockford GP. The breast cancer linkage consortium. Genetic linkage analysis in familial breast and ovarian cancer. Am J Med Genet. 1993;52(678–701). [PMC free article: PMC1682082] [PubMed: 8460634]
27.
Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000;83(10):1301–1308. [PMC free article: PMC2408797] [PubMed: 11044354]
28.
Antoniou AC, Pharoah PD, McMullan G. et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76–83. [PMC free article: PMC2746531] [PubMed: 11857015]
29.
Peto J, Collins N, Barfoot R. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11):943–949. [PubMed: 10359546]
30.
Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18(2):173–190. [PubMed: 10642429]
31.
American College of Medical Genetics Professional Practice and Guidelines Committee. Genetic susceptibility to breast and ovarian cancer: assessment, counseling, and testing guidelines executive summary. October 1999. Available at: http://www​.health.state​.ny.us/nysdoh/cancer​/obcancer/contents.htm. Accessed November 26, 2003.
32.
Statement of clinical oncology: Genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol. 1996;14(5):1730–1736. [PubMed: 8622094]
33.
Frank TS, Deffenbaugh AM, Reid JE. et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20(6):1480–1490. [PubMed: 11896095]
34.
Srivastava A, McKinnon W, Wood ME. Risk of breast and ovarian cancer in women with strong family histories. Oncology (Huntington). 2001;15(7):889–902. discussion 902, 905–887, 911–813. [PubMed: 11499690]
35.
Shattuck-Eidens D, Oliphant A, McClure M. et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997;278(15):1242–1250. [PubMed: 9333265]
36.
Couch FJ, DeShano ML, Blackwood MA. et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336(20):1409–1415. [PubMed: 9145677]
37.
Ad Hoc Committee on Genetic Counseling of the American Society of Human Genetics. Am J Hum Genet. 1975;27:240–242.
38.
Bowen DJ, Burke W, McTiernan A, Yasui Y, Anderson MR. Breast cancer risk counseling improves women's functioning. Patient Educ Couns. 2004;53:79–86. [PubMed: 15062908]
39.
Bowen DJ, Burke W, Yasui Y, McTiernan A, McLeran D. Effects of risk counseling on interest in breast cancer genetic testing for lower risk women. Genet Med. 2002;4(5):359–365. [PubMed: 12394349]
40.
Burke W, Culver JO, Bowen D. et al. Genetic counseling for women with an intermediate family history of breast cancer. Am J Med Genet. 2000;90(5):361–368. [PubMed: 10706356]
41.
Cull A, Miller H, Porterfield T. et al. The use of videotaped information in cancer genetic counselling: a randomized evaluation study. Br J Cancer. 1998;77(5):830–837. [PMC free article: PMC2149970] [PubMed: 9514066]
42.
Lerman C, Hughes C, Benkendorf JL. et al. Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Cancer Epidemiol Biomarkers Prev. 1999;8(4 Pt 2):361–367. [PubMed: 10207641]
43.
Lerman C. et al. A randomized trial of breast cancer risk counseling: interacting effects of counseling, educational level, and coping style. Health Psychology. 1996;15(2):75–83. [PubMed: 8681923]
44.
Lerman C, Lustbader E, Rimer B. et al. Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst. 1995;87(4):286–292. [PubMed: 7707420]
45.
Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet. 1998;32:95–121. [PubMed: 9928476]
46.
Myriad Genetic Laboratories, Inc. Available at: http://www​.myriadtests.com/home.htm. Accessed April 30, 2004.
47.
Unger MA, Nathanson KL, Calzone K. et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000;67(4):841–850. [PMC free article: PMC1287889] [PubMed: 10978226]
48.
U.S. Preventive Services Task Force Recommendations and Rationale: Screening for Breast Cancer. Available at: ahrq​.gov/clinic/uspstf/uspsbrca.htm. Ann Intern Med. 2002;137:344–346. [PubMed: 12204019]
49.
Burke W, Daly M, Garber J. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997;277(12):997–1003. [PubMed: 9091675]
50.
Kuhl CK, Schmutzler RK, Leutner CC. et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology. 2000;215(1):267–279. [PubMed: 10751498]
51.
Morris EA, Liberman L, Ballon DJ. et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol. 2003;181(3):619–626. [PubMed: 12933450]
52.
Kerlikowske K, Carney PA, Geller BM. et al. Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med. 2000;133:855–863. [PubMed: 11103055]
53.
Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effects of age, breast density, and family history on the sensitivity of first screening mammography. JAMA. 1996;276:33–38. [PubMed: 8667536]
54.
Chang J, Yang WT, Choo HF. Mammography in Asian patients with BRCA1 mutations. Lancet. 1999;353(9169):2070–2071. [PubMed: 10376643]
55.
Warner E, Plewes DB, Hill KA. et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–1325. [PubMed: 15367553]
56.
U.S. Preventive Services Task Force Recommendations and Rationale, Screening for Ovarian Cancer. 2004. Available at: http://www​.ahrq.gov/clinic​/3rduspstf/ovariancan/ovcanrs.htm. Accessed October 19, 2004.
57.
NIH Consensus Conference. Ovarian cancer: screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995;273(6):491–497. [PubMed: 7837369]
58.
Dhingra K. Antiestrogens—tamoxifen, SERMs and beyond. Invest New Drugs. 1999;17(3):285–311. [PubMed: 10665480]
59.
IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.[comment] Lancet. 2002;360(9336):817–824. [PubMed: 12243915]
60.
Fisher B, Costantino JP, Wickerham DL. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388. [PubMed: 9747868]
61.
Powles T, Eeles R, Ashley S. et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352(9122):98–101. [PubMed: 9672274]
62.
Veronesi U, Maisonneuve P, Costa A. et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 1998;352(9122):93–97. [PubMed: 9672273]
63.
Cuzick J, Powles T, Veronesi U. et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296–300. [PubMed: 12559863]
64.
Cummings SR, Eckert S, Krueger KA. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281(23):2189–2197. [PubMed: 10376571]
65.
Phase III randomized study of tamoxifen and raloxifene (STAR) for the prevention of breast cancer. 01-21-2004. Available at: http://www​.cancer.gov​/clinicaltrials/view_clinicaltrials​.aspx?version​=healthprofessional&cdrid​=67081&protocolsearchid=884140. Accessed April 20, 2004.
66.
Barrett-Connor E, Wenger NK, Grady D. et al. Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. J Womens Health. 1998;7(7):839–847. [PubMed: 9785310]
67.
Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937–947. [PMC free article: PMC1494944] [PubMed: 14687281]
68.
Curtis MG. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. Drug Safety. 2001;24(14):1039–1053. [PubMed: 11735660]
69.
U.S. Preventive Services Task Force Recommendations and Rationale: Chemoprevention of Breast Cancer. Available at: ahrq​.gov/clinic/uspstf/uspsbrpv.htm. Ann Intern Med. 2002;137(1):56–58. [PubMed: 12093249]
70.
Meijers-Heijboer H, van Geel B, van Putten WL. et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159–164. [PubMed: 11463009]
71.
Rebbeck TR, Friebel T, Lynch HT. et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–1062. [PubMed: 14981104]
72.
Rebbeck TR, Levin AM, Eisen A. et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475–1479. [PubMed: 10469748]
73.
Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer. 2002;38(Suppl 6):S15–17. [PubMed: 12409058]
74.
Kauff ND, Satagopan JM, Robson ME. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–1615. [PubMed: 12023992]
75.
Woods JE. Breast reconstruction: current state of the art. Mayo Clinic Proceedings. 1986;61:579–585. [PubMed: 3713262]
76.
Wapnir IL, Rabinowitz B, Greco RS. A reappraisal of prophylactic mastectomy. Surg Gynecol Obstet. 1990;171(2):171–184. [PubMed: 2200150]
77.
Goodnight JE, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol. 1984;26:198–201. [PubMed: 6330460]
78.
Pennisi VR, Capozzi A. Subcutaneous mastectomy data. Aesthetic Plast Surg. 1989;13:15–21. [PubMed: 2728994]
79.
Paley PJ, Swisher EM, Garcia RL. et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol. 2001;80:176–180. [PubMed: 11161856]
80.
Aziz S, Kuperstein G, Rosen B. et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001;80(3):341–345. [PubMed: 11263928]
81.
Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982;2(8302):795–797. [PubMed: 6126666]
82.
Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 1993;71(9):2751–2755. [PubMed: 8467455]
83.
Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC, Mok SC. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol. 1998;92:596–600. [PubMed: 9764635]
84.
Slavin RE. Best practice synthesis: an alternative to meta-analytic and traditional reviews. Education Research. 1986;15:5–11.
85.
Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389–1399. [PubMed: 11705483]
86.
Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999;64(4):963–970. [PMC free article: PMC1377820] [PubMed: 10090881]
87.
Cancer Genetics Network. Available at: http://epi.grants.center.gov/CGN/. Accessed March 20, 2005.
88.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7:177–188. [PubMed: 3802833]
89.
Bowen D, Christensen C, Powers D, Graves D, Anderson C. Effects of counseling and ethnic identity on perceived risk and cancer worry in African American women. Journal of Clinical Psychology in Medical Settings. 1998;5:365–379.
90.
Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998;105(5):493–499. [PubMed: 9637117]
91.
Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA. 2004;292(12):1480–1489. [PubMed: 15383520]
92.
Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol. 1997;146(3):244–248. [PubMed: 9247008]
93.
Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol. 2003;21(4):593–601. [PubMed: 12586794]
94.
Frank TS, Manley SA, Olopade OI. et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16(7):2417–2425. [PubMed: 9667259]
95.
Blackwood MA, Yang H, Margolin A. et al. Predicted probability of breast cancer susceptibility gene mutations. Breast Cancer Res Treat. 2001;69:223.
96.
Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89(3):227–238. [PubMed: 9017003]
97.
Berry DA, Iversen ES Jr, Gudbjartsson DF. et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701–2712. [PubMed: 12039933]
98.
Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62(1):145–158. [PMC free article: PMC1376797] [PubMed: 9443863]
99.
Euhus DM, Smith KC, Robinson L. et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002;94(11):844–851. [PubMed: 12048272]
100.
Euhus D. Risk modeling in breast cancer. Breast Journal. 2004;10(Suppl 1):S10–12. [PubMed: 14984482]
101.
CancerGene with BRCAPRO. The University of Texas Southwestern Medical Center at Dallas. Available at: www3.utsouthwestern.edu/cancergene. Accessed April 30, 2004.
102.
Cyrillic-Software. Available at: www​.cyrillicsoftware.com. Accessed April 30, 2004.
103.
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine. 2004;23:1111–1130. [PubMed: 15057881]
104.
Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clinical Genetics. 2000;58(4):299–308. [PubMed: 11076055]
105.
Claus EB, Risch H, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991;48:232–242. [PMC free article: PMC1683001] [PubMed: 1990835]
106.
Evans DGR, Eccles DM, Rahman N. et al. A new scoring system for the chances of identifying a BRCA 1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004;41:474–480. [PMC free article: PMC1735807] [PubMed: 15173236]
107.
Emery J, Walton R, Coulson A, Glasspool D, Ziebland S, Fox J. Computer support for recording and interpreting family histories of breast and ovarian cancer in primary care (RAGs): qualitative evaluation with simulated patients. BMJ. 1999;319(7201):32–36. [PMC free article: PMC28153] [PubMed: 10390458]
108.
Coulson AS, Glasspool DW, Fox J, Emery J. RAGs: A novel approach to computerized genetic risk assessment and decision support from pedigrees. Methods Inf Med. 2001;40(4):315–322. [PubMed: 11552344]
109.
Emery J, Walton R, Murphy M. et al. Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. BMJ. 2000;321(7252):28–32. [PMC free article: PMC27423] [PubMed: 10875832]
110.
Mouchawar J, Valentine Goins K, Somkin C. et al. Guidelines for breast and ovarian cancer genetic counseling referral: adoption and implementation in HMOs. Genet Med. 2003;5(6):444–450. [PubMed: 14614396]
111.
de Silva D, Gilbert F, Needham G, Deans H, Turnpenny P, Haites N. Identification of women at high genetic risk of breast cancer through the National Health Service Breast Screening Programme (NHSBSP). J Med Genet. 1995;32(11):862–866. [PMC free article: PMC1051736] [PubMed: 8592328]
112.
National Comprehensive Cancer Network. Breast Cancer Risk Reduction: Clinical Practice Guidelines in Oncology; 2004. [PubMed: 19768886]
113.
Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines: New York State Department of Health; 2004. Available at: www​.health.state.ny.us​/nysdoh/cancer/obcancer/pp6–12. Accessed March18, 2004.
114.
National Breast Cancer Centre (NBCC). Advice About Familial Aspects of Breast Cancer and Ovarian Cancer - A Guide for Health Professionals. Sydney, Australia: NBCC; 2000.
115.
de Bock GH, Vliet Vlieland TP, Hageman GC, Oosterwijk JC, Springer MP, Kievit J. The assessment of genetic risk of breast cancer: a set of GP guidelines. Fam Pract. 1999;16(1):71–77. [PubMed: 10321400]
116.
Pichert G, Stahel RA. Organizing cancer genetics programs: the Swiss model. J Clin Oncol. 2000;18(21 Suppl):65S–69S. [PubMed: 11060330]
117.
Hampel H, Sweet K, Westman JA, Offit K, Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet. 2004;41:81–91. [PMC free article: PMC1735676] [PubMed: 14757853]
118.
Lobb E, Butow P, Meiser B. et al. The use of audiotapes in consultations with women from high risk breast cancer families: a randomised trial. J Med Genet. 2002;39(9):697–703. [PMC free article: PMC1735239] [PubMed: 12205117]
119.
Watson M, Duvivier V, Wade Walsh M. et al. Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet. 1998;35(9):731–738. [PMC free article: PMC1051425] [PubMed: 9733031]
120.
Green MJ, Peterson SK, Baker MW. et al. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA. 2004;292(4):442–452. [PMC free article: PMC1237120] [PubMed: 15280342]
121.
Meiser B, Halliday JL. What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review. Social Science & Medicine. 2002;54(10):1463–1470. [PubMed: 12061481]
122.
Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. A psychological side effect of breast cancer screening. Health Psychology. 1991;10:259–267. [PubMed: 1915212]
123.
Centers for Disease Control Prevention. Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing—Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. MMWR Morbidity & Mortality Weekly Report. 2004;53(27):603–606. [PubMed: 15254451]
124.
Eng C, Brody LC, Wagner TM. et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet. 2001;38(12):824–833. [PMC free article: PMC1734796] [PubMed: 11748305]
125.
Fodor FH, Weston A, Bleiweiss IJ. et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 1998;63(1):45–51. [PMC free article: PMC1377227] [PubMed: 9634504]
126.
Struewing JP, Abeliovich D, Peretz T. et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.[erratum appears in Nat Genet 1996 Jan;12(1):110] Nat Genet. 1995;11(2):198–200. [PubMed: 7550349]
127.
Modan B, Hartge P, Hirsh-Yechezkel G. et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(4):235–240. [PubMed: 11474660]
128.
Oddoux C, Struewing JP, Clayton CM. et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% Nat Genet. 1996;14(2):188–190. [PubMed: 8841192]
129.
Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol. 2002;20(6):1570–1577. [PubMed: 11896106]
130.
Antoniou A, Pharoah PD, Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. [PMC free article: PMC1180265] [PubMed: 12677558]
131.
Ford D, Easton DF, Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62(3):676–689. [PMC free article: PMC1376944] [PubMed: 9497246]
132.
Hopper JL, Southey MC, Dite GS. et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev. 1999;8(9):741–747. [PubMed: 10498392]
133.
Risch HA, McLaughlin JR, Cole DE. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J HumGenet. 2001;68(3):700–710. [PMC free article: PMC1274482] [PubMed: 11179017]
134.
King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–646. [PubMed: 14576434]
135.
Moslehi R, Chu W, Karlan B. et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 2000;66(4):1259–1272. [PMC free article: PMC1288193] [PubMed: 10739756]
136.
Satagopan JM, Boyd J, Kauff ND. et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clinical Cancer Research. 2002;8(12):3776–3781. [PubMed: 12473589]
137.
Satagopan JM, Offit K, Foulkes W. et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2001;10(5):467–473. [PubMed: 11352856]
138.
Warner E, Foulkes W, Goodwin P. et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999;91(14):1241–1247. [PubMed: 10413426]
139.
Gayther SA, Mangion J, Russell P. et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15(1):103–105. [PubMed: 8988179]
140.
Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst. 2002;94(16):1221–1226. [PubMed: 12189225]
141.
Eccles DM, Englefield P, Soulby MA, Campbell IG. BRCA1 mutations in southern England. Br J Cancer. 1998;77(12):2199–2203. [PMC free article: PMC2150412] [PubMed: 9649133]
142.
Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med. 1996;334:137–142. [PubMed: 8531967]
143.
Malone KE, Daling JR, Neal C. et al. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000;88(6):1393–1402. [PubMed: 10717622]
144.
Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer. 2000;36(10):1200–1208. [PubMed: 10882857]
145.
Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA. 1998;279(12):915–921. [PubMed: 9544765]
146.
Sutcliffe S, Pharoah PD, Easton DF, Ponder BA. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. Int J Cancer. 2000;87(1):110–117. [PubMed: 10861460]
147.
Stratton JF, Gayther SA, Russell P. et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997;336(16):1125–1130. [PubMed: 9099656]
148.
Janezic SA, Ziogas A, Krumroy LM. et al. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Mol Genet. 1999;8(5):889–897. [PubMed: 10196379]
149.
Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet. 1999;65(4):1021–1029. [PMC free article: PMC1288234] [PubMed: 10486320]
150.
FitzGerald MG, MacDonald DJ, Krainer M. et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996;334(3):143–149. [PubMed: 8531968]
151.
Gershoni-Baruch R, Dagan E, Fried G. et al. Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer. 2000;36(8):983–986. [PubMed: 10885601]
152.
Abeliovich D, Kaduri L, Lerer I. et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997;60(3):505–514. [PMC free article: PMC1712523] [PubMed: 9042909]
153.
Robson M, Gilewski T, Hass B. et al. BRCA-associated breast cancer in young women. J Clin Oncol. 1998;16:1642–1649. [PubMed: 9586873]
154.
Boyd J, Sonoda Y, Federici MG. et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283(17):2260–2265. [PubMed: 10807385]
155.
Bish A, Sutton S, Jacobs C, Levene S, Ramirez A, Hodgson S. No news is (not necessarily) good news: impact of preliminary results for BRCA1 mutation searches. Genet Med. 2002;4(5):353–358. [PubMed: 12394348]
156.
Brain K, Norman P, Gray J, Rogers C, Mansel R, Harper P. A randomized trial of specialist genetic assessment: psychological impact on women at different levels of familial breast cancer risk. Br J Cancer. 2002;86(2):233–238. [PMC free article: PMC2375197] [PubMed: 11870512]
157.
Friedman LC, Webb JA, Richards CS. et al. Psychological impact of receiving negative BRCA1 mutation test results in Ashkenazim. Genet Med. 1999;1(3):74–79. [PubMed: 11336456]
158.
Hopwood P, Keeling F, Long A, Pool C, Evans G, Howell A. Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psycho-Oncology. 1998;7(5):402–412. [PubMed: 9809331]
159.
Lerman C, Hughes C, Lemon SJ. et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol. 1998;16(5):1650–1654. [PubMed: 9586874]
160.
Lobb EA, Butow PN, Barratt A. et al. Communication and information-giving in high-risk breast cancer consultations: influence on patient outcomes. Br J Cancer. 2004;90(2):321–327. [PMC free article: PMC2409563] [PubMed: 14735171]
161.
Meiser B, Butow P, Friedlander M. et al. Psychological impact of genetic testing in women from high-risk breast cancer families. Eur J Cancer. 2002;38(15):2025–2031. [PubMed: 12376208]
162.
Smith KE, West JA, Croyle RT, Botkin JR. Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. Cancer Epidemiol Biomarkers Prev. 1999;8(4):385–392. [PubMed: 10207644]
163.
Watson M, Lloyd S, Davidson J. et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer. 1999;79(56):868–874. [PMC free article: PMC2362694] [PubMed: 10070883]
164.
Bish A, Sutton S, Jacobs C, Levene S, Ramirez A, Hodgson S. Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women. Br J Cancer. 2002;86(1):43–50. [PMC free article: PMC2746544] [PubMed: 11857010]
165.
Fry A, Cull A, Appleton S. et al. A randomised controlled trial of breast cancer genetics services in South East Scotland: psychological impact. Br J Cancer. 2003;89(4):653–659. [PMC free article: PMC2376929] [PubMed: 12915873]
166.
Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG. Breast screening: the psychological sequelae of false-positive recall in women with and without a family history of breast cancer. Eur J Cancer. 1998;34(13):2010–2014. [PubMed: 10070302]
167.
Lodder LN, Frets PG, Trijsburg RW. et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat. 2002;73(2):97–112. [PubMed: 12088120]
168.
Lodder L, Frets PG, Trijsburg RW. et al. Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet. 2001;98(1):15–24. [PubMed: 11426450]
169.
Meiser B, Butow PN, Barratt AL. et al. Long-term outcomes of genetic counseling in women at increased risk of developing hereditary breast cancer. Patient Educ Couns. 2001;44(3):215–225. [PubMed: 11553422]
170.
Ritvo P, Robinson G, Irvine J. et al. Psychological adjustment to familial genetic risk assessment: differences in two longitudinal samples. Patient Educ Couns. 2000;40(2):163–172. [PubMed: 10771370]
171.
Warner E, Carroll JC, Heisey RE. et al. Educating women about breast cancer. An intervention for women with a family history of breast cancer. Can Fam Physician. 2003;49:56–63. [PMC free article: PMC2214123] [PubMed: 12602843]
172.
Burke W, Petersen G, Lynch P. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 1997;277(11):915–919. [PubMed: 9062331]
173.
Brekelmans CT, Seynaeve C, Bartels CC. et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19(4):924–930. [PubMed: 11181654]
174.
Chart PL, Franssen E. Management of women at increased risk for breast cancer: Preliminary results from a new program. Can Med Assoc J. 1997;157:1235–1242. [PMC free article: PMC1228353] [PubMed: 9361645]
175.
Gui GP, Hogben RK, Walsh G, A'Hern R, Eeles R. The incidence of breast cancer from screening women according to predicted family history risk: does annual clinical examination add to mammography? Eur J Cancer. 2001;37(13):1668–1673. [PubMed: 11527694]
176.
Kollias J, Sibbering DM, Blamey RW. et al. Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer. 1998;34(6):878–883. [PubMed: 9797701]
177.
Lai M, Yen M, Kuo H. et al. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer. 1998;78:21–26. [PubMed: 9724089]
178.
Lalloo F, Boggis CR, Evans DG, Shenton A, Threlfall AG, Howell A. Screening by mammography, women with a family history of breast cancer. Eur J Cancer. 1998;34(6):937–940. [PubMed: 9797712]
179.
Moller P, Maehle L, Heimdal K. et al. Inherited breast carcinoma—prospective findings in 1,194 women at risk. Acta Oncol. 1996;35(Suppl 8):7–11. [PubMed: 9073043]
180.
Saetersdal A, Dorum A, Heimdal K. et al. Inherited predisposition to breast carcinoma. Results of first round examination of 537 women at risk. Anticancer Research. 1996;16(4A):1989–1992. [PubMed: 8712731]
181.
Tilanus-Linthorst M, Bartels C, Obdeijn IM. et al. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer. 2000;36:514–519. [PubMed: 10717529]
182.
Komenaka IK, Ditkoff BA, Joseph K. et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer. 2004;100(10):2079–2083. [PubMed: 15139048]
183.
Scheuer L, Kauff N, Robson M. et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20(5):1260–1268. [PubMed: 11870168]
184.
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet. 1997;349(9064):1505–1510. [PubMed: 9167459]
185.
Fracheboud J, de Koning HJ, Beemsterboer PM. et al. Nationwide breast cancer screening in the Netherlands: results of initial and subsequent screening 1990-1995. Int J Cancer. 1998;75:694–698. [PubMed: 9495236]
186.
Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: The development of a monitoring and evaluation system. Br J Cancer. 1989;59:954–958. [PMC free article: PMC2246734] [PubMed: 2736233]
187.
Bourne TH, Campell S, Reynolds KM. et al. Screening for early familial ovarian cancer with transvaginal ultra sonography and colour blood flow imaging. BMJ. 1993;306(3884):1025–1029. [PMC free article: PMC1677026] [PubMed: 8490496]
188.
Wickerham DL. Tamoxifen versus raloxifene in the prevention of breast cancer. Eur J Cancer. 2002;38(Suppl 6):S20–S21. [PubMed: 12409060]
189.
King MC, Wieand S, Hale K. et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286(18):2251–2256. [PubMed: 11710890]
190.
Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA. 1996;276:1404–1408. [PubMed: 8892715]
191.
Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1999;130:270–277. [PubMed: 10068384]
192.
Cauley JA, Norton L, Lippman ME. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001;65(2):125–134. [PubMed: 11261828]
193.
Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol. 1990;43:559–568. [PubMed: 2348208]
194.
Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case control studies, II: invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1184–1203. [PubMed: 1476141]
195.
Franceschi S, Parazzini F, Negri E. Pooled analysis of 3 European case control studies of epithelial ovarian cancer, III: oral contraceptive use. Int J Cancer. 1991;49:61–65. [PubMed: 1874572]
196.
Narod SA, Risch H, Moslehi R. et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998;339(7):424–428. [PubMed: 9700175]
197.
Grabrick DM, Hartmann LC, Cerhan JR. et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000;284(14):1791–1798. [PubMed: 11025831]
198.
Ursin G, Henderson BE, Haile RW. et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Research. 1997;57(17):3678–3681. [PubMed: 9288771]
199.
McGuire V, Felberg A, Mills M. et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol. 2004;160(7):613–618. [PubMed: 15383404]
200.
Klaren HM, van't Veer LJ, van Leeuwen FE, Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst. 2003;95(13):941–947. [PubMed: 12837830]
201.
Hartmann LC, Schaid DJ, Woods JE. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77–84. [PubMed: 9887158]
202.
Hartmann LC, Sellers TA, Schaid DJ. et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633–1637. [PubMed: 11698567]
203.
Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr. 1995(17):33–35. [PubMed: 8573450]
204.
Brinton LA, Schairer C, Hoover R, Fraumeni JF Jr. Menstrual factors and risk of breast cancer. Cancer Invest. 1988;6:245–254. [PubMed: 3167610]
205.
Meijer WJ, van Lindert AC. Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol. 1992;47(1):59–65. [PubMed: 1426512]
206.
Parazzini F, Braga C, La Vecchia C, Negri E, Acerboni S, Franceschi S. Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet Gynecol. 1997;90(3):453–456. [PubMed: 9277661]
207.
Schairer C, Persson I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer. 1997;70(2):150–154. [PubMed: 9009152]
208.
Hankinson SE, Hunter DJ, Colditz G. Tubal ligation, hysterectomy and the risk of ovarian cancer. JAMA. 1993;270:2813–2818. [PubMed: 8133619]
209.
Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 1996;5(933–935). [PubMed: 8922304]
210.
Narod SA, Sun P, Ghadirian P. et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 2001;357(9267):1467–1470. [PubMed: 11377596]
211.
Law J. Cancers detected and induced in mammographic screening: new screening schedules and younger women with family history. Br J Radiol. 1997;70:62–69. [PubMed: 9059297]
212.
Day R. Quality of life and tamoxifen in a breast cancer prevention trial. Ann N Y Acad Sci. 2001;949:143–150. [PubMed: 11795346]
213.
Contant CM, Menke-Pluijmers MB, Seynaeve C. et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg Oncol. 2002;28(6):627–632. [PubMed: 12359199]
214.
Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 2000;18(9):1980–1995. [PubMed: 10784640]
215.
Weber BL. Familial breast cancer. Recent Results in Cancer Research. 1996;140:5–16. [PubMed: 8787076]
216.
Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291(13):1610–1620. [PubMed: 15069049]
217.
Cauley J, Robbins J, Chen Z. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Controlled Trial. JAMA. 2003;290:1729–1738. [PubMed: 14519707]
218.
Chlebowski R, Hendrix SL, Langer R. et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243–3253. [PubMed: 12824205]
219.
Committee WsHIS. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA. 2004;291:1701–1712. [PubMed: 15082697]
220.
Sellers TA, Mink PJ, Cerhan JR. et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127(11):973–980. [PubMed: 9412302]
221.
Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol. 2004;22(6):1045–1054. [PubMed: 14981106]
222.
Stefanek ME. Bilateral prophylactic mastectomy: issues and concerns. J Natl Cancer Inst Monogr. 1995(17):37–42. [PubMed: 8573451]
223.
Eisinger F, Reynier CJ, Chabal F, Luquet C, Moatti JP, Sobol H. Acceptable strategies for dealing with hereditary breast/ovarian cancer risk. J Natl Cancer Inst. 1997;89(10):731. [PubMed: 9168189]
224.
Grana G, Daly M, Sands C. The role of prophylactic mastectomy in managing genetic risk. Breast Cancer Res Treat. 1994;32(Suppl):72.
225.
Lerman C, Narod S, Schulman K. et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 1996;275(24):1885–1892. [PubMed: 8648868]
226.
Frost MH, Schaid DJ, Sellers TA. et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 2000;284(3):319–324. [PubMed: 10891963]
227.
Borgen PI, Hill AD, Tran KN. et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol. 1998;5(7):603–606. [PubMed: 9831108]
228.
Hatcher MB, Fallowfield L, A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. BMJ. 2001;322(7278):76. [PMC free article: PMC26594] [PubMed: 11154619]
229.
Tiller K, Meiser B, Butow P. et al. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol Oncol. 2002;86(2):212–219. [PubMed: 12144830]
230.
Nathorst-Boos J, von Schoultz B, Carlstrom K. Elective ovarian removal and estrogen replacement therapy—effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol. 1993;14(4):283–293. [PubMed: 8142982]
231.
Dennerstein L, Wood C, Burrows GD. Sexual response following hysterectomy and oophorectomy. Obstet Gynecol. 1977;49(1):92–96. [PubMed: 831167]
232.
Everson SA, Matthews KA, Guzick DS, Wing RR, Kuller LH. Effects of surgical menopause on psychological characteristics and lipid levels: the Healthy Women Study. Health Psychology. 1995;14(5):435–443. [PubMed: 7498115]
233.
Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psycho-Oncology. 2001;10(3):231–241. [PubMed: 11351375]
234.
Statement of the American Society of Clinical Oncology, Genetic testing for cancer susceptibility. Indications for genetic testing. SEER Data, , 1994. Available at: http://seer​.cancer.gov/. Accessed March 30, 2005.

Table 3

235.
Griffith GL, Edwards RT, Gray J. Cancer genetics services: a systematic review of the economic evidence and issues. Br J Cancer. 2004;90(9):1697–1703. [PMC free article: PMC2410279] [PubMed: 15150621]
236.
Breast and Ovarian Cancer Family Registries. Available at: http://epi.grants.center.gov/BCFR/. Accessed March 20, 2005.
237.
Progeny Software, LLC. Available at: www​.progeny2000.com. Accessed June 2004.
238.
Eccles DM, Evans DG, Mackay J. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). J Med Genet. 2000;37(3):203–209. [PMC free article: PMC1734545] [PubMed: 10699057]
239.
Moller P, Evans G, Haites N. et al. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Disease Markers. 1999;15(13):207–211. [PMC free article: PMC3850824] [PubMed: 10595280]
240.
Fries MH, Holt C, Carpenter I. et al. Guidelines for evaluation of patients at risk for inherited breast and ovarian cancer: recommendations of the Department of Defense Familial Breast/Ovarian Cancer Research Project. Military Medicine. 2002;167(2):93–98. [PubMed: 11873549]
241.
Lucassen A, Watson E, Harcourt J, Rose P, O'Grady J. Guidelines for referral to a regional genetics service: general practitioners respond by referring more appropriate cases. Family Practice. 2001;18(2):135–140. [PubMed: 11264262]
242.
Elwyn G, Iredale R, Gray J. Reactions of general practitioners to a triage-controlled referral system for cancer genetics. Family Practice. 2002;19(1):65–71. [PubMed: 11818352]
243.
Bowen D, McTiernan A, Burke W. et al. Participation in breast cancer risk counseling among women with a family history. Cancer Epidemiol Biomarkers Prev. 1999;8(7):581–585. [PubMed: 10428194]
244.
Daling JR, Malone KE, Voigt LF, White E, Weiss NS. Risk of breast cancer among young women: relationship to induced abortion. J Natl Cancer Inst. 1994;86:1584–92. [PubMed: 7932822]
245.
Brinton LA, Daling JR, Liff JM. et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87:827–35. [PubMed: 7791232]
246.
Wacholder S, Hartge P, Struewing JP. et al. The kin-cohort study for estimating penetrance. Am J Epidemiol. 1998;148(7):623–630. [PubMed: 9778168]
247.
Offit K. Breast cancer and BRCA1 mutations. N Engl J Med. 1996;334(18):1197–1198. [PubMed: 8602196]
248.
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004. Available at: http://seer​.cancer.gov/csr/1975_2001. Accessed October 19, 2004.
Bookshelf ID: NBK43295

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...